Mictoryl® Pediatric (propiverine hydrochloride) now covered by several public drug plans to treat symptoms associated with overactive bladder
BLAINVILLE, QC, June 7, 2018 /CNW Telbec/ - Duchesnay Inc., a specialty pharmaceutical company with a longstanding commitment to women's health, announced today that Mictoryl® Pediatric (propiverine hydrochloride 5 mg) has been added to the public drug plans of Alberta, New Brunswick, Ontario (limited use), Quebec and the Non-Insured Health Benefits (NIHB) Program.
Mictoryl® Pediatric is indicated for the symptomatic treatment of urinary incontinence and/or increased urinary frequency and urgency in pediatric patients, from the age of 5 years, with overactive bladder.
"There continues to be a need for new pediatric-specific therapies for children suffering from overactive bladder in Canada," said Éric Gervais, executive vice-president of Duchesnay. "We are pleased with these recent decisions to include Mictoryl® Pediatric in certain public drug plans, making a treatment with years of research and European market experience more accessible to Canadian families of children with overactive bladder."
About Mictoryl® Pediatric
About Duchesnay, Inc.
SOURCE Duchesnay inc.